Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; February 24, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 12,313 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.

GlobeNewsWire • 8 hours ago

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; February 23, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of DKK 725 million to honor our commitments under the Restricted Stock Unit program.

GlobeNewsWire • Feb 23, 2026

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; February 20, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.

GlobeNewsWire • Feb 20, 2026

Top 3 Health Care stocks That Could Lead To Your Biggest Gains In Q1

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga • Feb 19, 2026

Notice to Convene the Annual General Meeting of Genmab A/S

Company Announcement Genmab A/S to hold Annual General Meeting on Thursday March 19, 2026 COPENHAGEN, Denmark; February 18, 2026 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Thursday, March 19, 2026, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark. The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors, is attached.

GlobeNewsWire • Feb 18, 2026

Genmab Publishes 2025 Annual Report

Company Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025, financial performance for the year and the financial outlook for 2026.

GlobeNewsWire • Feb 17, 2026

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Media Release COPENHAGEN, Denmark; February 17, 2026 Genmab filed Form 20-F for the financial year 2025 with the U.S. SEC Genmab A/S (Nasdaq: GMAB ) a nnounced today that it has filed its Annual Report for the financial year 2025 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Genmab A/S Annual Report 2025. Both reports are available via the SEC's website, www.sec.gov and Genmab's website, www.genmab.com.

GlobeNewsWire • Feb 17, 2026

Genmab Announces Initiation of Share Buy-Back Program

Company Announcement Repurchase of up to 342,130 shares with a maximum aggregate total value of 725 million DKK Honoring our commitments under the Restricted Stock Unit program Completion expected no later than March 31, 2026 COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program, to honor our commitments under the Restricted Stock Unit program. The share buy-back program will be undertaken on the terms set out below and in accordance with Regulation (EU) No.

GlobeNewsWire • Feb 17, 2026

Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript

Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 17, 2026

Is the Options Market Predicting a Spike in Genmab Stock?

Investors need to pay close attention to GMAB stock based on the movements in the options market lately.

Zacks Investment Research • Feb 13, 2026